crimeancongo
haemorrhag
fever
cchf
sever
tickborn
diseas
endem
mani
countri
africa
middl
east
eastern
europ
asia
report
case
fatal
approv
vaccin
avail
preclin
protect
vivo
experiment
vaccin
demonstr
previous
present
studi
attenu
poxviru
vector
modifi
vaccinia
viru
ankara
use
develop
recombin
candid
vaccin
express
cchf
viru
glycoprotein
cellular
humor
immunogen
confirm
two
mous
strain
includ
type
interferon
receptor
knockout
mice
suscept
cchf
diseas
vaccin
protect
recipi
anim
lethal
diseas
challeng
model
adapt
repres
infect
via
tick
bite
histopatholog
viral
load
analysi
protect
anim
confirm
expos
challeng
viru
even
though
exhibit
clinic
sign
first
demonstr
efficaci
cchf
vaccin
new
tickborn
diseas
crimean
haemorrhag
fever
first
describ
crimea
recognis
viru
caus
diseas
ident
viru
isol
congo
diseas
subsequ
renam
crimeancongo
haemorrhag
fever
cchf
caus
agent
cchf
viru
cchfv
member
nairoviru
genu
bunyavirida
famili
peopl
may
infect
cchfv
bite
infect
ixodida
tick
contamin
tick
bodi
content
direct
contact
blood
tissu
bodi
fluid
infect
human
be
anim
effici
common
tick
vector
appear
member
hyalomma
genu
commonli
infest
livestock
anim
cchf
caus
sever
human
diseas
fatal
rate
due
haemorrhag
natur
diseas
also
caus
nosocomi
infect
healthcar
worker
although
clinic
predictor
mortal
develop
correl
protect
fulli
understood
detect
antibodi
respons
usual
requir
surviv
predict
recoveri
therefor
like
antibodi
lymphocyt
requir
protect
cchf
endem
mani
countri
asia
middl
east
eastern
europ
southern
africa
increas
problem
western
europ
includ
popular
tourism
destin
greec
turkey
incid
geograph
rang
cchf
increas
nonendem
countri
also
risk
import
case
octob
fatal
case
cchf
occur
travel
return
uk
afghanistan
addit
concern
potenti
use
cchfv
bioterror
agent
led
us
nation
institut
allergi
infecti
diseas
list
viru
categori
c
prioriti
pathogen
due
sever
diseas
eas
transmiss
fact
antivir
compound
vaccin
proven
effect
cchfv
classifi
hazard
group
pathogen
uk
advisori
committe
danger
pathogen
progress
cchfv
research
sever
hamper
lack
suitabl
anim
model
newborn
mice
succumb
infect
due
immatur
immun
system
use
assess
vaccin
efficaci
recent
howev
adult
small
anim
model
develop
use
mice
defici
type
interferon
ifn
signal
pathway
either
type
ifn
receptor
ifnabr
cchfv
infect
ifnabrknockout
mice
replic
human
diseas
via
varieti
inocul
rout
includ
subcutan
inject
intend
mimic
human
infect
tick
bite
vaccin
base
cchfv
amplifi
suckl
mous
brain
inactiv
chloroform
treatment
use
eastern
europ
unlicens
european
medicin
agenc
us
food
drug
administr
recent
studi
found
elicit
cellular
humor
respons
cchfv
neutralis
antibodi
titr
low
even
peopl
receiv
dose
control
studi
protect
efficaci
report
vaccin
due
crude
prepar
unlik
gain
widespread
intern
regulatori
approv
develop
vaccin
meet
current
intern
standard
need
genom
cchfv
distribut
three
rna
segment
small
medium
larg
l
encod
viral
nucleoprotein
glycoprotein
rna
polymeras
respect
segment
approxim
kbp
length
encod
polyprotein
precursor
undergo
proteolyt
cleavag
event
contain
singl
open
read
frame
residu
strain
process
matur
glycoprotein
g
n
g
c
three
domain
asyet
unknown
function
variabl
mucinlik
domain
domain
nsm
domain
g
n
g
c
glycoprotein
cchfv
bind
target
cell
influenc
infect
cell
tropism
target
neutralis
antibodi
viru
entri
thought
primarili
mediat
g
c
bind
propos
viru
receptor
human
cell
surfac
nucleolin
recent
vaccin
approach
cchf
includ
dnabas
vaccin
express
cchfv
segment
induc
neutralis
antibodi
approxim
half
vaccin
mice
lack
challeng
model
time
meant
efficaci
could
demonstr
anoth
vaccin
candid
use
transgen
tobacco
leav
express
g
n
g
c
fed
mice
induc
igg
iga
howev
antibodi
test
neutralis
titr
oral
vaccin
test
protect
neither
studi
investig
cellular
immun
respons
therefor
present
safe
effect
commerciallyavail
vaccin
cchfv
poxvir
vector
vaccin
base
modifi
vaccinia
viru
ankara
mva
capac
accommod
larg
gene
insert
cchfv
segment
despit
growth
defici
mammalian
cell
mva
abl
promot
highlevel
gene
express
recombin
gene
vitro
vivo
authent
posttransl
modif
host
cell
humor
cellular
immun
induc
mva
without
requir
adjuv
aim
develop
candid
vaccin
base
recombin
mva
express
cchfv
glycoprotein
assess
induct
cellular
humor
immun
evalu
efficaci
challeng
model
repres
human
diseas
adapt
previous
describ
anim
model
mimic
infect
tick
bite
establish
intraderm
deliveri
cchfv
ifnabr
defici
mice
first
demonstr
cchf
vaccin
candid
confer
protect
preclin
model
femal
ifnabr
mice
age
week
obtain
b
k
univers
uk
immunocompromis
anim
hous
asept
environ
protect
opportunist
infect
effort
made
minimis
anim
suffer
endpoint
limit
moder
sever
rate
studi
approv
ethic
review
process
public
health
england
porton
uk
home
offic
uk
via
project
licenc
number
work
perform
accord
anim
scientif
procedur
act
home
offic
uk
code
practic
hous
care
anim
use
scientif
procedur
cell
obtain
atcc
usa
cultur
modifi
essenti
eagl
medium
sigmaaldrich
usa
supplement
foetal
bovin
serum
fb
mm
lglutamin
u
penicillin
mgml
streptomycin
sigmaaldrich
cef
cell
obtain
institut
anim
health
compton
uk
cultur
dulbecco
modifi
eagl
medium
sigmaaldrich
supplement
access
number
vero
access
number
cell
obtain
european
collect
cell
cultur
uk
cultur
maintain
leibovitz
medium
contain
glutamax
life
technolog
uk
supplement
fb
virus
mva
strain
mva
clone
kindli
suppli
prof
b
moss
nih
usa
viru
titr
determin
plaqu
assay
cell
cchfv
strain
amplifi
suckl
mous
brain
homogenis
dispos
pestl
mortar
titr
determin
tcid
vero
cell
cassett
contain
gateway
system
recombin
sequenc
life
technolog
usa
gener
upstream
side
adjac
kozak
sequenc
start
codon
follow
human
tissu
plasminogen
activ
tpa
leader
sequenc
amino
acid
residu
downstream
side
adjac
residu
linker
sequenc
follow
residu
epitop
stop
codon
cassett
insert
xmai
sali
restrict
site
plasmid
kindli
provid
prof
b
moss
nih
produc
plasmid
segment
nucleic
acid
sequenc
cchf
strain
access
number
modifi
remov
untransl
region
initi
termin
codon
enabl
gateway
recombin
sequenc
ad
begin
end
respect
remain
open
read
frame
ie
nucleotid
two
poxviru
transcript
stop
signal
tttttnt
posit
alter
without
introduc
code
chang
result
sequenc
synthesis
recombin
pdonr
life
technolog
entelechon
germani
gener
plasmid
pentrgp
plasmid
pentrgp
recombin
use
gateway
technolog
gener
plasmid
ptpgp
cell
infect
mva
multipl
infect
infect
cell
transfect
ptpgp
use
lipofectamin
life
technolog
direct
manufactur
result
recombin
mvagp
serial
plaquepurifi
time
cell
base
green
fluoresc
protein
gfp
express
mvagp
amplifi
cef
cell
purifi
sucros
cushion
centrifug
titrat
plaqu
assay
cell
prior
use
vivo
studi
plaqu
visualis
use
gfp
fluoresc
immunostain
rabbit
antivaccinia
antibodi
abd
serotec
uk
vectastain
univers
abcap
kit
vector
laboratori
usa
genom
dna
infect
cell
extract
use
wizard
sv
genom
dna
purif
system
promega
usa
use
templat
pcr
accuprim
taq
dna
polymeras
high
fidel
life
technolog
genotyp
analysi
group
mice
age
week
inject
intramuscularli
caudal
thigh
plaqueform
unit
pfu
per
anim
mvagp
dilut
endotoxinfre
pb
control
anim
receiv
pfuanim
nonrecombin
mva
equival
volum
salin
total
volum
ml
deliv
anim
across
two
site
ml
anim
receiv
booster
vaccin
day
later
anim
euthanis
tissu
collect
day
primari
vaccin
spleen
vaccin
anim
collect
asept
homogenis
red
blood
cell
lyse
splenocyt
resuspend
rpmi
medium
sigmaaldrich
supplement
fb
mm
lglutamin
u
penicillin
mgml
streptomycin
mm
mm
hepe
solut
sigmaaldrich
splenocyt
assess
antigen
recal
respons
via
ifnc
elispot
mabtech
sweden
perform
per
manufactur
instruct
cell
seed
pvdf
microtitr
plate
per
well
restimul
peptid
pool
mimotop
australia
peptid
span
fusion
protein
sequenc
residu
long
overlap
residu
peptid
appli
cell
final
concentr
mgml
per
peptid
peptid
per
pool
plate
develop
hour
co
humidifi
incub
spot
count
visual
autom
elispot
reader
autoimmun
diagnostika
germani
background
valu
well
contain
cell
medium
peptid
subtract
pool
sum
across
target
protein
result
express
spot
form
unit
sfu
per
cell
use
western
blot
analysi
cell
monolay
infect
cchfv
multipl
infect
incub
uc
leibovitz
medium
contain
fb
medium
remov
hour
postinfect
cell
treat
laemmli
buffer
supplement
contain
sodium
dodecyl
sulphat
sigmaaldrich
result
mixtur
collect
vial
heat
treat
uc
least
minut
uninfect
monolay
treat
similarli
neg
control
sucros
cushionpurifi
mva
lysat
cchfvinfect
uninfect
cell
subject
sdspage
bistri
gel
life
technolog
protein
transfer
pvdf
membran
block
milk
protein
oxoid
uk
membran
incub
primari
antibodi
hour
wash
time
pb
contain
sigmaaldrich
sigmaaldrich
incub
hour
hrpconjug
secondari
antibodi
wash
bound
antibodi
detect
eclprim
wb
detect
reagent
ge
life
scienc
usa
accord
manufactur
instruct
visual
chemidoc
system
biorad
usa
molecular
weight
calcul
comparison
marker
known
molecular
weight
use
quantityon
softwar
primari
antibodi
use
mous
abd
serotec
dilut
polyclon
rabbit
serum
kindli
provid
mirazimi
sweden
rais
glycoprotein
peptid
dilut
serum
vaccin
mice
dilut
secondari
antibodi
antimous
igg
sigmaaldrich
dilut
antimous
iggam
abd
serotec
dilut
antirabbit
igg
sigmaaldrich
primari
antibodi
serum
vaccin
mice
dilut
made
pb
contain
milk
protein
western
blot
dilut
made
pb
contain
milk
protein
recombin
g
n
ectodomain
express
mammalian
system
kindli
provid
dr
thoma
bowden
univers
oxford
uk
dilut
carbonatebicarbon
buffer
ph
sigmaaldrich
use
coat
maxisorp
plate
nunc
denmark
ngwell
volum
ml
well
plate
cover
plate
sealer
incub
overnight
wash
twice
mlwell
pb
use
aquamax
molecular
devic
usa
plate
washer
plate
block
mlwell
skim
milk
powder
pb
hour
shake
wash
three
time
sampl
dilut
skim
milk
powder
pb
ad
plate
mlwell
triplic
incub
hour
shake
normal
mous
serum
sigmaaldrich
use
neg
control
sampl
plate
wash
three
time
addit
mlwell
polyclon
hrpconjug
goat
antimous
iggam
abd
serotec
dilut
skim
milk
powder
pb
altern
hrpconjug
goat
antimous
igm
sigmaaldrich
dilut
use
hour
incub
shake
plate
wash
three
time
abt
elisa
hrp
substrat
kpl
usa
prepar
accord
manufactur
instruct
mlwell
ad
incub
room
temperatur
minut
shake
reaction
stop
mlwell
abt
peroxidas
stop
solut
kpl
prepar
accord
manufactur
instruct
optic
densiti
measur
nm
spectramax
multimod
spectrophotomet
molecular
devic
parameterlogist
curv
fit
plot
sampl
softmax
pro
version
molecular
devic
endpoint
titr
interpol
dilut
absorb
ratio
expect
observ
endpoint
titr
intern
refer
sampl
use
correct
factor
compar
sampl
across
multipl
plate
cchfv
challeng
mice
mice
receiv
tcid
cchfv
unless
otherwis
state
volum
ml
intraderm
upper
medial
area
back
subsequ
anim
weigh
monitor
bodi
temperatur
daili
addit
observ
clinic
sign
twice
daili
sign
ill
convert
numer
score
follow
normal
arch
ruffl
arch
ruffl
lethargi
immobl
anim
show
moder
sign
eg
loss
bodi
weight
lethargi
immobl
euthanis
day
postchalleng
randomli
select
surviv
anim
kill
human
sampl
blood
spleen
liver
collect
viral
load
studi
spleen
liver
histopatholog
examin
day
postchalleng
surviv
anim
kill
human
sampl
collect
day
postchalleng
addit
approxim
cm
section
liver
spleen
harvest
asept
store
uc
subsequ
viral
amplif
anim
euthanis
time
point
spleen
liver
sampl
collect
histopatholog
examin
sampl
histopatholog
examin
place
neutral
buffer
formalin
day
process
routin
paraffin
wax
section
cut
mm
stain
haematoxylin
eosin
examin
microscop
immunohistochemistri
formalinfix
paraffinembed
section
spleen
liver
cut
mm
mount
posit
charg
xtra
adhes
slide
leica
biosystem
uk
deparaffinis
rehydr
immunohistochem
stain
achiev
use
bondmax
immunostain
leica
microsystem
uk
novacastra
bond
intens
r
leica
biosystem
detect
kit
heatinduc
epitop
retriev
cycl
buffer
r
leica
biosystem
perform
minut
slide
incub
rabbit
serum
abcam
cambridg
uk
minut
follow
avidinbiotin
block
stage
minut
abcam
polyclon
antibodi
rais
sheep
immunis
recombin
cchfv
nucleoprotein
kindli
provid
dr
john
barr
univers
leed
uk
incub
tissu
minut
follow
biotinyl
rabbit
antisheep
polyclon
antibodi
abcam
dilut
minut
haematoxylin
use
counterstain
posit
neg
control
slide
includ
immunolabel
slide
evalu
use
light
microscopi
whole
blood
ml
collect
rna
protect
anim
blood
tube
qiagen
netherland
store
tube
thaw
invert
left
hour
room
temperatur
ensur
effici
cell
lysi
sampl
treat
red
blood
cell
lysi
solut
miltenyi
biotec
germani
purif
total
rna
use
rneasi
mini
kit
qiagen
viral
load
analysi
spleen
liver
sampl
collect
rnalat
qiagen
store
thaw
tissu
transfer
rlt
buffer
qiagen
homogenis
pass
mm
siev
treat
use
rneasi
mini
kit
qiagen
extract
total
rna
cchfv
segment
detect
rtpcr
abi
rtpcr
platform
describ
adjust
cycl
condit
minut
minut
follow
cycl
second
second
quantif
analysi
fluoresc
perform
end
step
final
cool
second
sampl
also
analys
level
hypoxanthin
guanin
phosphoribosyl
transferas
hprt
housekeep
gene
onestep
rtpcr
singleplex
detect
perform
target
bp
product
mous
hprt
gene
ncbi
refer
sequenc
use
quantifast
probe
assay
qiagen
abi
rtpcr
platform
reaction
run
triplic
normalis
cchfv
express
data
c
valu
cchfv
hprt
invert
subtract
c
valu
total
number
cycl
c
number
cycl
requir
reach
fluoresc
threshold
valu
mean
valu
cchfv
divid
mean
valu
hprt
refer
gene
sampl
tissu
thaw
homogenis
mm
mesh
ml
leibovitz
medium
contain
glutamax
supplement
fb
supernat
clarifi
centrifug
minut
ml
ad
cm
flask
cell
clinic
isol
cchfv
use
posit
control
viru
present
left
absorb
minut
ml
medium
ad
flask
incub
day
cell
observ
microscop
cytopath
effect
due
data
distribut
nonparametr
mannwhitney
u
test
perform
determin
statist
signific
group
data
analysi
conduct
use
figur
schemat
represent
vaccin
vector
nucleotid
cchfv
segment
orang
fuse
aminoterminu
amino
acid
residu
tpa
leader
sequenc
via
residu
deriv
gateway
recombin
process
carboxyterminu
fuse
amino
acid
residu
epitop
via
residu
gateway
sequenc
residu
linker
peptid
product
control
promot
mva
flank
insert
delet
iii
site
mva
genom
insert
cassett
also
contain
enhanc
gfp
gene
downstream
promot
identif
recombin
viru
mucinlik
domain
repres
mu
transfer
plasmid
ptpgp
prepar
describ
materi
method
encod
fusion
protein
nucleotid
downstream
poxviru
promot
flank
mva
genom
sequenc
insert
delet
iii
region
mva
ptpgp
also
encod
enhanc
gfp
gene
downstream
poxviru
promot
insert
locu
fig
sequenc
insert
cassett
given
file
plasmid
ptpgp
use
gener
recombin
mva
viru
name
mvagp
express
full
length
segment
open
read
frame
glycoprotein
fuse
signal
sequenc
tpa
aminoterminu
increas
immunogen
intracellular
transport
epitop
fuse
carboxyterminu
short
linker
sequenc
immunodetect
vitro
protein
express
total
residu
also
incorpor
final
recombin
gene
product
footprint
attb
sequenc
use
gateway
recombin
mvagp
also
express
gfp
enumer
plaqu
gfp
visualis
compar
immunostain
antivaccinia
antibodi
confirm
absenc
gfpneg
viru
pcr
insert
site
produc
singl
recombinantspecif
product
fail
amplifi
parentspecif
product
data
shown
indic
absenc
parent
mva
sequenc
insert
site
confirm
spontan
mutat
transgen
introduc
sdspage
mvagp
western
blot
antibodi
fig
indic
singl
protein
approxim
kda
confirm
express
consist
cleavag
predict
kda
fusion
protein
gp
precursor
rkpl
sequenc
sdspage
western
blot
antiglycoprotein
polyclon
serum
perform
order
compar
glycoprotein
express
mvagp
cchfv
fig
slight
shift
toward
higher
molecular
weight
protein
observ
g
c
express
mvagp
compar
express
cchfv
may
explain
epitop
tag
add
kda
unclear
cchfvexpress
g
c
g
n
appear
lower
molecular
weight
previous
report
abil
mvagp
induc
gpspecif
ifnc
cellular
respons
test
week
old
mice
wildtyp
parent
strain
mice
per
group
vaccin
pfuanim
mvagp
mva
equival
volum
salin
day
day
day
cull
human
splenocyt
serum
harvest
sampl
liver
spleen
also
taken
histolog
analysi
repeat
independ
studi
old
mice
n
mice
per
group
use
histolog
examin
stain
lesion
liver
spleen
detect
vaccin
anim
day
therefor
detect
patholog
caus
vaccin
ifnc
elispot
result
splenocyt
prepar
day
show
mvagp
immunis
mice
gener
cellular
immun
respons
specif
cchfv
glycoprotein
fig
respons
viral
glycoprotein
subdivid
separ
peptid
pool
pool
optim
mous
strain
wherea
peptid
pool
consist
nonimmunogen
peptid
pool
induc
highest
elispot
respons
map
larg
nsm
nterminu
g
c
mucinlik
domain
respect
major
g
n
protein
except
ctermin
residu
fell
peptid
pool
map
pool
induc
specif
tcell
respons
central
ctermin
region
g
c
map
peptid
pool
also
fail
stimul
cell
interestingli
nonstructur
domain
therefor
contain
highli
immunogen
tcell
epitop
statist
differ
immun
respons
observ
strain
mice
mvagp
vaccin
show
effect
abrog
type
ifn
receptor
tcell
induc
vaccin
respons
tcell
respons
peptid
deriv
tpa
region
irrelev
antigen
cchfv
nucleoprotein
neglig
indic
specif
respons
fig
vaccin
anim
also
test
induct
cchfvspecif
humor
respons
mvagp
use
western
blot
igg
antibodi
react
protein
approxim
kda
detect
vaccin
anim
sera
mice
collect
day
vaccin
schedul
fig
mice
cchfvspecif
igg
antibodi
respons
detect
western
blot
individu
anim
recognis
kda
protein
fig
randomli
select
mous
receiv
mva
neg
control
test
cchfvspecif
antibodi
respons
seen
fig
sera
anim
vaccin
mvagp
also
assess
western
blot
earli
phase
immun
respons
use
detector
antibodi
specif
mous
igg
iga
igm
antibodi
specif
kda
cchfv
protein
detect
anim
test
posit
antiigg
fig
sinc
pattern
protein
recognit
individu
similar
assay
ie
fig
infer
antibodi
recognis
kda
protein
predominantli
igg
broaden
sensit
addit
antibodi
class
way
detect
antibodi
specif
protein
approxim
kda
fig
anim
individu
therefor
igm
probabl
predomin
antibodi
class
sinc
iga
expect
serum
sera
remain
mice
recognis
cchfvspecif
protein
data
shown
separ
studi
week
old
mice
vaccin
intramuscularli
pfuanim
mvagp
mva
mice
per
group
day
anim
receiv
booster
vaccin
day
day
sera
collect
heat
inactiv
pool
pool
contain
sera
anim
pool
mvagp
vaccin
anim
igg
antibodi
respons
protein
approxim
kda
detect
fig
remain
pool
could
adequ
assess
due
high
background
stain
like
caus
sever
haemolysi
pool
one
serum
pool
mva
vaccin
control
group
test
igg
antibodi
reactiv
observ
collect
evid
indic
mice
mount
humor
respons
recognis
similar
antigen
ev
immunocompet
mice
kinet
delay
day
vaccin
protocol
day
postboost
anim
detect
igg
respons
contrast
anim
underw
class
switch
igm
igg
day
investig
antibodi
respons
serum
pool
day
also
test
indirect
elisa
g
n
ectodomain
assay
specif
igg
iga
igm
sever
haemolys
pool
exclud
analysi
due
nonspecif
reactiv
show
true
differ
sampl
absorb
endpoint
valu
select
manual
curv
parallel
fig
lower
limit
detect
assay
endpoint
titr
lowest
dilut
factor
use
four
pool
mice
vaccin
mvagp
test
reach
endpoint
titr
one
pool
mice
vaccin
mva
weakli
posit
endpoint
titr
remain
pool
test
lower
limit
detect
fig
therefor
mvagp
vaccin
specif
induc
antibodi
recognis
g
n
although
mvagp
vaccin
pool
posit
cchfvspecif
antibodi
respons
notabl
higher
might
due
sera
strongli
respond
anim
pool
togeth
due
presenc
serum
nonrespond
lower
titr
pool
assay
repeat
use
conjug
specif
igm
sampl
neg
data
shown
iga
expect
serum
conclud
posit
sampl
therefor
contain
predominantli
igg
day
establish
lethal
dose
cchfv
viru
dilut
pb
intraderm
inocul
week
old
mice
concentr
tcid
anim
per
group
demonstr
tcid
lowest
dose
caus
infect
mice
reach
human
clinic
endpoint
sixweek
old
mice
per
group
vaccin
mvagp
mva
pfuanim
equival
volum
salin
day
anim
receiv
booster
vaccin
day
day
anim
challeng
tcid
cchfv
intraderm
ie
doubl
minimum
lethal
dose
four
day
challeng
day
randomli
select
anim
group
sacrif
histolog
examin
viral
load
test
day
postchalleng
day
remain
anim
kill
human
sampl
collect
histolog
viral
load
test
anim
control
group
began
show
clinic
sign
day
challeng
increas
sever
anim
euthanis
day
postchalleng
fig
b
contrast
anim
receiv
mvagp
vaccin
clinic
sign
day
postchalleng
day
studi
stop
point
vaccin
anim
surviv
time
longer
control
group
consid
pass
beyond
critic
phase
diseas
anim
protect
diseas
exhibit
initi
rise
bodi
temperatur
follow
sharp
reduct
succumb
contrast
temperatur
mvagp
vaccin
anim
remain
stabl
throughout
studi
fig
control
anim
lost
origin
bodi
weight
within
day
challeng
wherea
weight
mvagp
vaccin
mice
remain
stabl
throughout
studi
fig
liver
one
anim
receiv
mva
prior
cchfv
challeng
appear
normal
day
vaccin
schedul
challeng
anim
mva
salin
group
show
lesion
spleen
liver
tabl
spleen
microscop
chang
compris
patchi
diffus
infiltr
parenchyma
macrophag
primarili
involv
red
pulp
vari
degre
effac
white
pulp
fig
latter
involv
lymphocyt
loss
apoptosi
characteris
tingibl
bodi
macrophag
apoptot
bodi
liver
chang
compris
multifoc
diffus
hepatocyt
necrosi
characteris
cytoplasm
eosinophilia
nuclear
pyknosi
accompani
frequent
mix
inflammatori
cell
infiltr
mainli
polymorphonuclear
leukocyt
fig
mvagp
group
day
spleen
minim
chang
seen
two
three
anim
fig
one
anim
moder
chang
identifi
liver
characteris
multifoc
chang
hepatocyt
necrosi
mix
inflammatori
cell
infiltr
fig
remain
six
anim
group
surviv
day
lesion
identifi
select
sampl
also
examin
immunohistochemistri
tabl
mva
salinetr
anim
posit
stain
present
spleen
liver
includ
posit
stain
two
anim
vaccin
mva
exhibit
clinic
sign
spleen
major
posit
cell
appear
macrophag
red
pulp
scatter
cell
white
pulp
fig
liver
sampl
anim
clinic
sign
diffus
posit
cytoplasm
stain
hepatocyt
fig
two
anim
vaccin
mva
show
clinic
sign
kill
human
day
posit
stain
predominantli
kupffer
cell
macrophag
line
sinusoid
fig
contrast
mvagp
group
spleen
anim
examin
day
day
show
stain
fig
liver
anim
stain
posit
day
remain
anim
neg
occasion
hepatocyt
scatter
inflammatori
foci
show
posit
stain
fig
indic
inflammatori
respons
viral
antigen
viral
load
analys
rtpcr
cchfv
segment
blood
spleen
liver
anim
per
group
day
vaccin
schedul
surviv
anim
day
cchfv
express
normalis
express
hprt
refer
gene
fig
control
group
day
viral
rna
detect
tissu
test
statist
signific
differ
salin
mva
mvagp
vaccin
group
day
viral
rna
detect
blood
two
three
anim
although
anim
detect
viral
rna
spleen
liver
normalis
cchfv
express
significantli
lower
mvagp
vaccin
anim
compar
control
group
tissu
p
day
viral
rna
detect
blood
vaccin
mice
detect
tissu
test
statist
signific
differ
day
day
sampl
mvagp
vaccin
anim
investig
whether
infecti
viru
still
present
end
studi
homogenis
supernat
spleen
liver
tissu
survivor
day
includ
viraem
individu
incub
viral
cultur
condit
hour
although
cytopath
effect
usual
observ
timepoint
posit
control
isol
cultur
parallel
induc
extens
cytopath
none
mous
survivor
sampl
induc
observ
cytopath
effect
possibl
longer
cultur
period
may
necessari
observ
cytopath
preliminari
result
suggest
rna
detect
day
unlik
repres
viabl
viru
develop
mvavector
candid
vaccin
cchf
base
fulllength
glycoprotein
precursor
encod
cchfv
segment
mva
proven
safeti
record
use
latter
stage
smallpox
erad
campaign
mva
inexpens
manufactur
gmp
establish
regulatori
packag
develop
investig
new
drug
proven
clinic
safeti
record
induct
humor
cellular
antigenspecif
immun
respons
thermost
applic
remot
region
without
establish
cold
chain
make
mva
promis
viral
vector
deliv
potenti
cchf
vaccin
inde
mva
vaccin
current
clinic
trial
phase
iii
diseas
includ
tuberculosi
malaria
hivaid
cancer
influenza
hepat
c
glycoprotein
often
target
novel
vaccin
design
even
highli
variabl
pathogen
influenza
viru
see
review
sinc
expos
posit
virion
surfac
make
access
antibodi
bind
neutralis
cchf
glycoprotein
precursor
undergo
coand
posttransl
proteolyt
cleavag
event
endoplasm
tabl
sever
microscop
lesion
stain
tissu
vaccin
mice
challeng
cchfv
reticulum
golgi
bodi
conserv
motif
rskr
rrll
rkpl
complex
seri
matur
step
caus
difficulti
attempt
express
recombin
g
n
g
c
vitro
use
viral
vector
deliveri
system
bypass
problem
like
lead
authent
protein
express
pattern
g
n
g
c
contain
golgi
localis
signal
interact
two
glycoprotein
requir
g
c
travel
golgi
therefor
although
g
c
may
contain
neutralis
protect
epitop
inclus
g
n
vaccin
design
may
advantag
effect
assist
correct
traffick
work
vaccin
candid
encod
nonstructur
accessori
domain
mucin
like
domain
nsm
well
g
n
g
c
similar
candid
dna
vaccin
describ
spik
et
al
contrast
oral
vaccin
express
g
n
g
c
structur
protein
reli
nglycosyl
g
n
correct
fold
transport
g
n
turn
complex
matur
process
involv
sequenti
cleavag
accessori
domain
mucinlik
domain
requir
correct
transport
g
n
golgi
apparatu
complex
interplay
product
glycoprotein
precursor
absenc
critic
compon
could
unexpect
effect
process
express
antigen
mvagp
vaccin
fulllength
glycoprotein
open
read
frame
control
poxviru
promot
increas
stabil
strong
earli
express
drive
cytotox
tlymphocyt
respons
leader
sequenc
human
tpa
ad
increas
immunogen
intracellular
transport
ad
identif
express
protein
immunolabel
intraderm
challeng
rout
chosen
cchfv
infect
model
sinc
close
resembl
major
natur
rout
infect
via
tick
bite
incub
period
cchf
human
gener
vari
day
long
day
shorter
incub
period
associ
acquir
infect
tick
bite
compar
contact
infect
human
blood
nosocomi
transmiss
shorter
incub
period
associ
fatal
outcom
similar
studi
tickborn
pathogen
also
model
infect
diseas
use
intraderm
rout
experiment
mimic
tick
bite
includ
use
ehrlichia
lyme
diseas
rickettsia
previou
characteris
cchfv
infect
mous
model
focus
intraperiton
rout
although
recent
paper
also
characteris
inocul
rout
includ
subcutan
time
onset
clinic
sign
surviv
time
unprotect
group
seen
studi
consist
seen
zivcec
et
al
challeng
dose
tcid
deliv
subcutan
howev
lethal
dose
observ
group
tcid
compar
tcid
present
studi
differ
could
explain
inocul
rout
use
subcutan
versu
intraderm
genet
background
mice
use
versu
histopatholog
lesion
seen
liver
spleen
stain
immunohistochemistri
consist
previou
observ
work
cellmedi
humor
immun
respons
assess
mous
model
without
fulli
function
innat
immun
immunogen
data
addit
mhc
genet
background
would
interest
would
limit
valu
without
abil
follow
efficaci
studi
characteris
immun
respons
convalesc
patient
could
illustr
type
protect
immun
requir
effect
vaccin
howev
clinic
studi
examin
cellular
immun
respons
cchf
akinci
et
al
report
antibodi
level
found
significantli
higher
level
cell
fatal
case
compar
nonfat
case
correl
viral
load
therefor
cchf
induc
prolifer
cytotox
tcell
incap
control
infect
fatal
case
anoth
report
also
found
elev
level
cell
paediatr
cchf
case
fatal
outcom
studi
group
comparison
order
effici
captur
immun
respons
mvagp
vaccin
peptid
use
elispot
assay
amino
acid
residu
length
approach
shown
stimul
cell
subset
posit
tcell
respons
seen
group
surviv
lethal
challeng
immunogen
studi
requir
termin
sacrific
howev
analysi
prechalleng
immun
respons
surviv
studi
occur
differ
individu
correl
could
therefor
appli
group
whole
reason
variabl
tcell
immunogen
observ
across
glycoprotein
domain
unclear
encourag
highest
level
seen
conserv
domain
mucinlik
domain
highli
variabl
across
cchfv
strain
differ
aminoacid
ident
compar
differ
rest
glycoprotein
open
read
frame
although
relev
cellular
respons
protect
still
unknown
promis
design
vaccin
confer
crossstrain
protect
clinic
cchf
immun
studi
examin
serum
antibodi
level
nucleoprotein
patient
fatal
outcom
weak
absent
antibodi
respons
ozturk
et
al
found
signific
differ
igm
igg
level
fatal
vs
nonfat
case
howev
studi
unabl
find
signific
relationship
presenc
igm
igg
antibodi
clinic
outcom
found
viral
load
better
predictor
prognosi
viru
titr
decreas
survivor
first
week
diseas
independ
antibodi
suggest
critic
role
innat
cellular
immun
mechan
monoclon
antibodi
rais
viral
glycoprotein
identifi
protect
epitop
g
n
g
c
howev
antibodi
recognis
epitop
g
c
neutralis
vitro
therefor
direct
neutralis
mechan
antibodi
protect
cchf
protect
antibodi
also
found
crossreact
across
cchfv
clade
encourag
design
vaccin
confer
crossstrain
protect
report
found
antibodi
recognit
similar
cchfv
glycoprotein
wildtyp
mous
strain
respons
mice
howev
slightli
delay
day
vaccin
schedul
anim
detect
igg
respons
howev
time
point
humor
respons
detect
assay
specif
broaden
includ
igm
respons
unlik
transient
sinc
predominantli
igg
respons
detect
addit
day
protect
mediat
via
humor
respons
igg
requir
longterm
immun
memori
wherea
igm
like
provid
short
term
protect
diseas
although
igg
observ
day
time
challeng
mice
longer
interv
vaccin
challeng
need
confirm
vaccin
induc
immun
memori
quantit
elisa
also
found
vari
level
specif
antibodi
pool
sera
approxim
vaccin
mice
day
booster
administ
unfortun
possibl
test
individu
sera
time
point
quantit
rang
individu
respons
sampl
avail
prior
pool
sinc
cchfvinfect
cell
lysat
could
valid
elisa
recombin
g
n
ectodomain
use
captur
antigen
therefor
vaccineinduc
antibodi
specif
domain
would
detect
assay
specif
antibodi
seen
group
surviv
lethal
challeng
individu
detect
respons
use
either
method
describ
therefor
direct
correl
could
drawn
induct
cchfvspecif
antibodi
protect
day
postchalleng
randomli
select
anim
sacrif
viral
load
analysi
histolog
examin
includ
anim
mva
group
display
clinic
sign
ill
immunohistochemistri
liver
sampl
anim
detect
viral
antigen
kupffer
cell
associ
kupffer
cell
also
note
knockout
model
cchfv
human
case
immunohistochemistri
therefor
abl
distinguish
mvagp
vaccin
control
vaccin
individu
absenc
clinic
sign
probabl
mvagp
vaccin
anim
complet
free
infect
develop
subclin
diseas
viral
rna
detect
anim
four
day
postchalleng
posit
correl
viral
load
sever
diseas
observ
patient
consist
observ
mous
model
end
efficaci
studi
viral
rna
still
detect
surviv
anim
although
individu
detect
viraemia
although
consist
level
viral
load
seen
day
day
may
indic
ongo
subclin
viral
replic
like
rna
releas
defect
viral
particl
viru
inactiv
effect
immun
eg
neutralis
antibodi
initi
attempt
amplifi
live
viru
day
tissu
sampl
unsuccess
therefor
possibl
vaccin
induc
sterilis
immun
exclud
interestingli
prolong
viraemia
assess
rtpcr
also
observ
convalesc
patient
studi
report
attempt
recov
viabl
viru
mvagp
vaccin
induc
comprehens
cellular
humor
immun
cchfv
translat
protect
sever
diseas
clinic
sign
ill
appar
studi
furthermor
adapt
immun
respons
elicit
vaccin
substanti
affect
absenc
type
ifn
receptor
mice
protect
correl
tcell
respons
antibodi
induct
although
studi
requir
determin
exactli
protect
compon
direct
work
could
also
includ
test
longev
demonstr
protect
effect
investig
whether
mvagp
confer
protect
multipl
cchfv
strain
report
provid
first
demonstr
protect
cchf
candid
vaccin
lethal
anim
challeng
model
valid
applic
ifnabr
knockout
adult
mous
model
mvabas
vaccin
approach
give
promis
modern
cchf
vaccin
meet
intern
regulatori
approv
possibl
current
data
look
extrem
promis
repres
major
progress
search
medic
intervent
use
protect
cchf
file
sequenc
insert
full
nucleotid
sequenc
insert
cassett
use
gener
mvagp
translat
fusion
protein
also
given
docx
analysi
geoff
pearson
also
provid
use
comment
manuscript
prepar
